Title: Large-Scale Validation of a Flow Cytometry Platform for Comprehensive Immunophenotyping, Cell Size Determination, and Prognostic Stratification in Canine Lymphomas.
Karim Mrouj1, Jerry Cromarty1, Sheena Kapoor1, Sushmita Sen1, Josephine Tsang1, Surya Vishnubhatt1, Deanna Swartzfager1, Stanley Park1, Sungwon Lim1 George Courcoubetis1, Ilona Holcomb1
1ImpriMed, Inc., Mountain View, CA 94043, USA
Introduction
Accurate immunophenotyping and cell size determination are essential for diagnosing and for prognosticating canine lymphomas. While the integration of flow cytometry with PARR significantly enhances diagnostic precision, the true potential of flow cytometry in refining prognostic outcomes still requires robust validation. We evaluate the efficacy of a flow cytometry platform for immunophenotyping and cell size measurement within a large clinical cohort, aiming to advance its prognostic capabilities.
Methods
We performed a retrospective analysis of flow cytometry data encompassing 1000 canine lymphoma cases. Our immunophenotyping results were compared with reference laboratories to evaluate concordance. In a targeted subset, we correlated flow cytometry-derived cell size measurements with cytological assessments. Additionally, we scrutinized the prognostic implications linking immunophenotypes to clinical outcomes.
Results
Immunophenotyping of canine samples achieved a concordance rate exceeding 98% with reference methods. The assessment of cell size revealed a strong correlation with cytological findings across the canine cohort. Furthermore, categorizing T-cell lymphoma subtypes by immunophenotype effectively identified specific clusters that correlate with distinct clinical prognoses. These findings underscore the prognostic significance of select markers and cell size across both prevalent and rarer lymphoma subtypes.
Conclusion
This large-scale validation establishes our flow cytometry platform as an exceptionally reliable tool for immunophenotyping and cell size determination. Beyond its diagnostic capabilities, the wealth of data offers crucial prognostic insights. By integrating these refined flow cytometric findings into clinical practice, we have the potential to significantly enhance therapeutic stratification and optimize patient management, ultimately improving outcomes for these patients.
